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Abstract
Background: Most meta-analyses include data from one or more small studies that, individually, do not have power to
detect an intervention effect. The relative influence of adequately powered and underpowered studies in published meta-
analyses has not previously been explored. We examine the distribution of power available in studies within meta-analyses
published in Cochrane reviews, and investigate the impact of underpowered studies on meta-analysis results.
Methods and Findings: For 14,886 meta-analyses of binary outcomes from 1,991 Cochrane reviews, we calculated power
per study within each meta-analysis. We defined adequate power as $50% power to detect a 30% relative risk reduction. In
a subset of 1,107 meta-analyses including 5 or more studies with at least two adequately powered and at least one
underpowered, results were compared with and without underpowered studies. In 10,492 (70%) of 14,886 meta-analyses, all
included studies were underpowered; only 2,588 (17%) included at least two adequately powered studies. 34% of the meta-
analyses themselves were adequately powered. The median of summary relative risks was 0.75 across all meta-analyses
(inter-quartile range 0.55 to 0.89). In the subset examined, odds ratios in underpowered studies were 15% lower (95% CI
11% to 18%, P,0.0001) than in adequately powered studies, in meta-analyses of controlled pharmacological trials; and 12%
lower (95% CI 7% to 17%, P,0.0001) in meta-analyses of controlled non-pharmacological trials. The standard error of the
intervention effect increased by a median of 11% (inter-quartile range 21% to 35%) when underpowered studies were
omitted; and between-study heterogeneity tended to decrease.
Conclusions: When at least two adequately powered studies are available in meta-analyses reported by Cochrane reviews,
underpowered studies often contribute little information, and could be left out if a rapid review of the evidence is required.
However, underpowered studies made up the entirety of the evidence in most Cochrane reviews.
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Introduction
Systematic reviews of intervention studies aim to synthesise all
available evidence meeting pre-specified eligibility criteria. Such
criteria seldom address sample size. Meta-analyses may therefore
include data from one or more small studies which, individually,
do not have power to detect a modest intervention effect. Small
studies tend to report greater intervention effects than larger
studies [1]. So-called ‘‘small-study effects’’ may arise from
reporting biases, whereby findings in smaller studies are more
likely to be selected for publication on the basis of statistical
significance [2]. Alternatively, small-study effects may arise from
biases caused by methodological flaws arising more frequently in
small studies [3], or may be due to true differences in the
underlying effects between smaller and larger studies.
Some researchers argue for excluding small studies from meta-
analyses. Specifically to reduce the effects of publication bias,
Stanley suggested discarding 90% of the study estimates, so that
conclusions are based on only the most precise 10% of studies [4].
Earlier, Kraemer proposed including only adequately powered
studies in meta-analysis, both to remove publication bias and to
discourage future researchers from carrying out small studies [5].
In teaching, Bird has long advocated that trials should not be
started unless they could deliver at least 50% power in respect of a
priori plausible, worthwhile effect sizes [6]. The prospect of
inclusion in later meta-analyses may partly explain why investi-
gators continue to feel justified in conducting underpowered
studies [7–9]. Researchers who choose to undertake a study that is
capable of detecting only an unrealistically large effect may lack
understanding of both scientific methods and ethics [10].
Arguments for including small studies in meta-analyses uphold
that evidence synthesis is best informed by all reasonably unbiased
evidence and that no such evidence should be discarded lightly.
Cut-offs based on study size, although scientifically cost-efficient,
introduce an extra element of subjectivity and might not
ameliorate bias if the remaining large studies are insufficiently
critiqued [11]. Moreover, observing heterogeneity in effects across
multiple independent trials is important, even if some of these are
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smaller, since this is likely to reflect heterogeneity that would occur
in clinical practice [12;13]. Difficulties caused by reporting biases
and related small-study effects can be addressed through statistical
methods of adjustment [14;15].
In this paper, we explore the levels of power available in studies
included in published meta-analyses, and examine the relative




To examine power per study within meta-analyses and to
explore whether this varies across different settings, we use
evidence from the Cochrane Database of Systematic Reviews (CDSR:
Issue 1, 2008), which was provided by the Nordic Cochrane
Centre. Each meta-analysis was categorized by type of outcome,
types of intervention compared, and medical specialty to which the
research question related, as described elsewhere [16]. In this
paper, we include all meta-analyses of binary outcomes that
reported data from two or more studies (14,886 meta-analyses).
Calculation of Power per Study
In meta-analysis j, power was calculated with respect to a fixed
baseline event rate, ~pj0. The median of the observed proportions
experiencing events was calculated for each intervention arm
separately and the higher median was used as ~pj0. For each study i
within meta-analysis j (with mean number of patients ni per
treatment arm), we calculated how much power the study sample
size provided to detect a relative risk reduction of 10%, 20%, 30%
or 50% (or, equivalently, a relative risk of hR =0.9, 0.8, 0.7 or 0.5).
For convenience, we refer to a relative risk reduction of 30%, for
example, as RRR30. In study i within meta-analysis j, the power to
detect a difference between event rates ~pj0 and hR~pj0 at a














where W is the cumulative standard normal distribution function
and Ca=2~W
{1 1{a=2ð Þ. For our primary analyses we define
adequate power as $50% power to detect RRR30. In subsequent
analyses, we fitted a random-effects model to obtain a summary
relative risk estimate, h^j , for meta-analysis j, and calculated the
power of study i to detect the treatment effect observed in the
meta-analysis to which it contributed, i.e. to detect a difference
between ~pj0 and h^j~pj0.
Calculation of power per Meta-analysis
The focus of this paper is on the power of primary studies within
meta-analyses, but it is interesting also to examine the power of the
meta-analyses themselves. In each meta-analysis j, we fitted a
random-effects model, using a method-of-moments estimate for
the between study variance [17], and calculated the variance Vj of
the combined intervention effect (on the log relative risk scale).
The power of meta-analysis j to detect a 30% relative risk
reduction or equivalently a log relative risk of d~ log 0:7ð Þ, using a













where W is the cumulative standard normal distribution function
and Ca=2~W
{1 1{a=2ð Þ[18].
Impact of Underpowered Studies
We defined subset A as CDSR meta-analyses that include five or
more studies, with at least two adequately powered
(PowerRRR30§50%) with respect to RRR30 and at least one
underpowered (PowerRRR30v50%), to investigate the impact of
including or excluding underpowered studies. On the log odds
ratio scale, per meta-analysis, we fitted fixed-effect and random-
effects models including (1) all studies; (2) adequately powered
studies only (PowerRRR30§50%) or (3) underpowered studies only
(PowerRRR30v50%).
For meta-analyses relating to beneficial rather than adverse
outcomes, the data were rearranged, so that an odds ratio below 1
favours the experimental intervention over the comparator across
all meta-analyses in subset A. A method-of-moments estimate was
used for the between-study variance in the random-effects model
[17].
As a descriptive analysis of the impact of excluding underpow-
ered studies in subset A meta-analyses, we calculated ratios
comparing meta-analysis results obtained from all studies with
results from adequately powered studies only.
To compare effect sizes formally within subset A, we first
estimated the average difference between log odds ratios in
underpowered studies (PowerRRR30v50%) compared with ade-
quately powered studies (PowerRRR30§50%) by fitting a random-
effects meta-regression model. Then, in a random effects meta-
analysis, we combined the estimated differences across subset A
meta-analyses, with or without adjustment separately for (i)
medical specialties, (ii) outcome type, (iii) intervention type. We
also explored the role of underpowered studies in individual meta-
analyses within a particular research setting in more detail, as
described in Appendix S1.
Results
Power of Studies Included in Cochrane Reviews
Table 1 summarizes power of primary studies within meta-
analyses in the CDSR database. In 10,492 (70%) of the 14,886
CDSR meta-analyses, all studies were underpowered
(PowerRRR30v50%) to detect a 30% relative risk reduction
(RRR30). In many settings, a 20% relative risk reduction would
be more realistic, and 85% of the meta-analyses included no
studies powered to detect RRR20. Only 2,588 (17%) meta-analyses
included at least two studies powered at 50% or more to detect
RRR30, and only 1,291 (9%) included at least two studies powered
at 80% or more. Median power within CDSR meta-analyses was
low for RRR30 at 13% power, with an inter-quartile range (iqr) of
7% to 31% power. Some studies were generously powered, with
2,571/77,237 (3.3%) having at least 98% power for RRR30
(Figure 1).
Power of studies to detect the summary relative risk in their
meta-analysis was also low: 11,422 (77%) meta-analyses included
no studies with $50% power and only 2,236 (15%) meta-analyses
included at least two studies with $50% power. The median of
summary relative risks was 0.75 across all meta-analyses (iqr 0.55
to 0.89).
The Impact of Study Size on Meta-Analyses
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Table 2 summarizes power for RRR30 by medical specialty,
outcome and intervention-comparison type. In cancer, 35% of 689
meta-analyses included at least two adequately powered studies,
and only 365 meta-analyses (53%) consisted entirely of under-
powered studies. However, median power within cancer meta-
analyses remained low at 24% power (iqr 10% to 57% power).
By outcome, we expected power to be lower for events that are
typically rare. Power was indeed somewhat lower for meta-
analyses reporting all-cause mortality and cause-specific mortality/
major morbidity event/composite (mortality or morbidity), and
somewhat higher for meta-analyses relating to resource use, signs/
symptoms reflecting continuation/end of disease or a mixture of
subjective outcomes (see Table 2).
Power of Meta-analyses Included in Cochrane Reviews
Table 3 summarizes the power of the meta-analyses themselves
to detect a 30% relative risk reduction, overall and by medical
specialty, outcome and intervention-comparison type. Overall, the
proportion of meta-analyses with 80% power or more to detect
RRR30 was 22%, with a further 12% powered at 50–80% to
detect RRR30, but 66% were underpowered. At 34%, the
proportion of adequately powered meta-analyses was substantially
larger than the proportion of meta-analyses including at least two
adequately powered studies, but remains low.
The median of meta-analytic power was 27% (iqr 11% to 72%
power). There was some variation across medical areas; in cancer,
51% of meta-analyses were powered at 50% or more. Differences
in meta-analytic power across medical areas, outcome and
intervention-comparison types were largely in the same direction
as differences in meta-analysis summaries of study power (Table 2).
Impact of Excluding Underpowered Studies from Meta-
analyses
Of the 14,886 CDSR meta-analyses with binary outcomes, 1,107
(7.4%) were eligible for inclusion in subset A. The impact of
excluding the underpowered trials on the results of these meta-
analyses is summarised in Table 4. We calculated ratios comparing
log odds ratio estimates from a meta-analysis of adequately
powered studies only to those from a full meta-analysis. These are
shown for fixed-effect and random-effects models separately.
Across the 1,107 meta-analyses, there was a broad spread of
ratios representing changes to the summary log odds ratio. The
Figure 1. Distribution of power available to detect a relative risk reduction of 30%, across 77,237 studies.
doi:10.1371/journal.pone.0059202.g001
Table 1. Percentages of 14,886 meta-analyses including no studies adequately powered to detect a target effect or including at










at least 2 studies
Median (IQR) of median
power within meta-analyses
10% relative risk reduction (RRR10) 98% 0.6% 96% 2% 0.05 (0.03 to 0.07)
20% relative risk reduction (RRR20) 92% 3% 85% 8% 0.08 (0.05 to 0.16)
30% relative risk reduction (RRR30) 83% 9% 70% 17% 0.13 (0.07 to 0.31)
50% relative risk reduction (RRR50) 62% 24% 46% 38% 0.31 (0.13 to 0.69)
Summary relative risk observed in meta-analysis 86% 8% 77% 15% 0.08 (0.04 to 0.26)
doi:10.1371/journal.pone.0059202.t001
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median ratio was 0.96 for the fixed-effect model and 0.94 for the
random-effects model. The results correspond to a slight shift
towards the null value when underpowered studies were removed,
more so under the random-effects model in which small studies
have greater influence.
Under the random-effects model, it is possible for precision to
be gained (i.e. smaller standard error) when studies are removed, if
the heterogeneity estimate is sufficiently reduced. The non-zero
between-study heterogeneity in 851 meta-analyses decreased by a
median of 21% when underpowered studies were removed (iqr
296% to +18%).
Table 5 presents average differences in log odds ratios between
inadequately powered (PowerRRR30v50%) and adequately pow-
ered studies, obtained from fitting meta-epidemiological models to
the subset of 1,107 meta-analyses. Overall, the difference was
20.10 (95% CI 20.13 to 20.08, P,0.0001), which corresponds
to odds ratios in underpowered studies being 10% lower on
average (95% CI 8% to 13%), where lower odds ratios represent
more extreme effects in favour of the active treatment. There was
Table 2. Numbers of adequately powered studies ($50% power) and median power within each meta-analysis (MA) with respect
to a 30% relative risk reduction (RRR30), overall and by medical specialty, outcome type and intervention-comparison type.
N
% of MA in which
all studies
underpowered
% of MA in which $2
studies adequately
powered
Median (IQR) of median
power within meta-
analyses
All meta-analyses 14886 70% 17% 0.13 (0.07 to 0.31)
Medical specialty
Cancer 689 53% 35% 0.24 (0.10 to 0.57)
Cardiovascular 1192 68% 19% 0.11 (0.06 to 0.26)
Central nervous system/musculoskeletal 1210 79% 11% 0.13 (0.06 to 0.26)
Digestive/endocr., nutritional and metabolic 1464 75% 16% 0.11 (0.05 to 0.28)
Gynaecology, pregnancy and birth 3905 72% 15% 0.11 (0.06 to 0.28)
Infectious diseases 780 62% 23% 0.16 (0.08 to 0.42)
Mental health and behavioural conditions 1977 73% 17% 0.14 (0.08 to 0.32)
Pathological conditions, symptoms and signs 414 64% 20% 0.17 (0.08 to 0.39)
Respiratory diseases 1310 75% 15% 0.12 (0.07 to 0.27)
Urogenital 932 77% 12% 0.12 (0.06 to 0.25)
Other medical specialties1 1013 61% 24% 0.18 (0.08 to 0.41)
Outcome types
Objective outcomes
All-cause mortality 1132 77% 14% 0.08 (0.05 to 0.18)
Semi-objective outcomes
Obstetric outcomes 1288 71% 15% 0.12 (0.07 to 0.25)
Cause-specific mortality/major morbidity event/composite
(mortality or morbidity)
907 76% 14% 0.08 (0.05 to 0.18)
Resource use/hospital stay/process 680 59% 22% 0.20 (0.08 to 0.42)
Other semi-objective outcomes2 1711 79% 12% 0.10 (0.06 to 0.22)
Subjective outcomes
Adverse events 2330 81% 11% 0.11 (0.06 to 0.21)
Signs/symptoms reflecting continuation/end of condition 2184 54% 30% 0.25 (0.12 to 0.52)
Infection/onset of new acute/chronic disease 2038 75% 13% 0.11 (0.06 to 0.24)
Biological markers (dichotomised) 947 66% 21% 0.16 (0.07 to 0.39)
General physical health 276 75% 11% 0.13 (0.08 to 0.25)
Other subjective outcomes3 1331 59% 24% 0.22 (0.11 to 0.46)
Intervention-comparison types
Pharmacological vs. Control/Placebo 5599 68% 18% 0.13 (0.07 to 0.31)
Non-pharmacological4 vs. Control/Placebo 2412 59% 26% 0.19 (0.08 to 0.47)
Active vs. Active 6875 76% 14% 0.11 (0.06 to 0.26)
1Other medical specialties: Blood and immune system, Ear and nose, Eye, General health, Genetic disorders, Injuries, accidents and wounds, Mouth and dental, Skin.
2Other semi-objective outcomes: External structure, Internal structure, Surgical/device related success/failure, Withdrawals/drop-outs.
3Other subjective outcomes: Pain, Mental health outcomes, Quality of life/functioning, Consumption, Satisfaction with care, Composite (at least 1 non-mortality/
morbidity).
4Non-pharmacological interventions include interventions classified as medical devices, surgical, complex, resources and infrastructure, behavioural, psychological,
physical, complementary, educational, radiotherapy, vaccines, cellular and gene, screening.
doi:10.1371/journal.pone.0059202.t002
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evidence that differences in log odds ratios varied across medical
areas (P = 0.001), and across intervention-comparison types
(P = 0.0002), but not by outcome types (P = 0.83). By medical
area, the greatest differences between inadequately and adequately
powered studies were observed for infectious diseases, mental
health and behavioural conditions, gynaecology, pregnancy and
birth, and in the mixed subset of ‘‘other medical specialties’’
(defined in footnote to Table 2). In comparisons of two active
interventions, the results are less meaningful since the direction of
the intervention effect is likely to vary across meta-analyses in the
data set. Odds ratios in underpowered studies were 15% lower
(95% CI 11% to 18%, P,0.0001) in meta-analyses comparing
pharmacological interventions against control or placebo, and
12% lower (95% CI 7% to 17%, P,0.0001) in meta-analyses
comparing non-pharmacological interventions against control or
placebo.
In Appendix S1, the role of underpowered studies in individual
meta-analyses is explored in more detail.
Discussion
Underpowered studies made up the entirety of the evidence in
most meta-analyses reported by Cochrane reviews: in 70% of
CDSR meta-analyses, all studies had less than 50% power to detect
a 30% relative risk reduction (RRR30), and only 17% of meta-
analyses included at least two studies with at least 50% power for
RRR30. There was some variation across medical areas and
outcome types, but individual studies’ power was low across all
types of meta-analyses.
Table 3. Meta-analytic power with respect to a 30% relative risk reduction (RRR30), based on the random-effects model, overall
and by medical specialty, outcome type and intervention-comparison type.
N
% of MA in which
meta-analytic power
$50%
% of MA in which
meta-analytic power
$80%
Median (IQR) of meta-
analytic power
All meta-analyses 14886 34% 22% 0.27 (0.11 to 0.72)
Medical specialty
Cancer 689 51% 39% 0.51 (0.19 to 0.99)
Cardiovascular 1192 40% 28% 0.32 (0.12 to 0.86)
Central nervous system/musculoskeletal 1210 25% 13% 0.21 (0.10 to 0.50)
Digestive/endocr., nutritional and metabolic 1464 32% 21% 0.23 (0.10 to 0.68)
Gynaecology, pregnancy and birth 3905 31% 20% 0.23 (0.09 to 0.65)
Infectious diseases 780 35% 22% 0.27 (0.11 to 0.74)
Mental health and behavioural conditions 1977 38% 24% 0.32 (0.12 to 0.78)
Pathological conditions, symptoms and signs 414 37% 18% 0.31 (0.12 to 0.67)
Respiratory diseases 1310 34% 21% 0.28 (0.11 to 0.71)
Urogenital 932 27% 16% 0.24 (0.11 to 0.55)
Other medical specialties1 1013 39% 28% 0.35 (0.12 to 0.86)
Outcome types
Objective outcomes
All-cause mortality 1132 36% 25% 0.24 (0.10 to 0.81)
Semi-objective outcomes
Obstetric outcomes 1288 38% 25% 0.31 (0.12 to 0.79)
Cause-specific mortality/major morbidity event/composite
(mortality or morbidity)
907 33% 22% 0.22 (0.09 to 0.67)
Resource use/hospital stay/process 680 41% 27% 0.36 (0.12 to 0.83)
Other semi-objective outcomes2 1711 29% 18% 0.22 (0.10 to 0.59)
Subjective outcomes
Adverse events 2330 24% 13% 0.19 (0.09 to 0.48)
Signs/symptoms reflecting continuation/end of condition 2184 46% 33% 0.42 (0.17 to 0.93)
Infection/onset of new acute/chronic disease 2038 28% 17% 0.22 (0.10 to 0.55)
Biological markers (dichotomised) 947 32% 21% 0.24 (0.10 to 0.69)
General physical health 276 29% 14% 0.26 (0.11 to 0.57)
Other subjective outcomes3 1331 45% 28% 0.41 (0.16 to 0.86)
Intervention-comparison types
Pharmacological vs. Control/Placebo 5599 35% 22% 0.29 (0.12 to 0.73)
Non-pharmacological4 vs. Control/Placebo 2412 43% 28% 0.36 (0.13 to 0.87)
Active vs. Active 6875 30% 19% 0.23 (0.10 to 0.62)
1Other medical specialties, semi-objective outcomes, subjective outcomes and non-pharmacological interventions defined in footnotes to Table 2.
doi:10.1371/journal.pone.0059202.t003
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In a meta-epidemiological analysis of 1,107 meta-analyses, we
found that odds ratios in underpowered studies were on average
10% lower (95% CI 8% to 12%, P,0.0001) than those in
adequately powered studies. This should be regarded as a lower
limit on the difference, since the database contains treatment
comparisons that have underlying relative risks either side of 1.
Indeed, the difference was larger among comparisons involving a
control or placebo group (15% for controlled pharmaceutical
trials), in which we might expect the direction of effect to be more
consistent across meta-analyses. In meta-analyses in which at least
two adequately powered studies are available, underpowered
studies often had relatively little impact on the summary estimate
of the odds ratio. The summary estimate shifted slightly toward the
null when underpowered studies were removed, under both fixed-
effect and random-effects models. The extent to which precision
was lost when underpowered studies were excluded varied across
Table 4. Ratios comparing results obtained from adequately powered studies only with results obtained from all studies, in subset
A of 1,107 meta-analyses: results shown are percentiles of the distribution of such ratios across meta-analyses.
Percentile
5% 25% 50% 75% 95%
Ratio of log OR estimates from fixed-effect (FE) meta-analysis, adequately powered studies only
vs.all studies
20.17 0.78 0.96 1.06 1.76
Ratio of log OR estimates from random-effects (RE) meta-analysis, adequately powered studies
only vs. all studies
20.40 0.67 0.94 1.10 1.85
Ratio of FE standard errors for log OR, adequately powered studies only vs. all studies 1.01 1.04 1.11 1.26 1.72
Ratio of RE standard errors for log OR, adequately powered studies only vs. all studies 0.63 0.99 1.11 1.35 2.20
Ratio of heterogeneity estimates, adequately powered studies only vs. all studies (where t^2
non-zero for all studies)1
0 0.04 0.79 1.18 2.81
1t^2~0 in the all-studies meta-analysis in 256/1107 meta-analyses. In 199/256 (78%), t^2~0 also in the meta-analysis including adequately powered studies only. In 57/
256 (22%), t^2 increased, but trivially, when underpowered studies were removed.
doi:10.1371/journal.pone.0059202.t004
Table 5. Average differences in observed log odds ratios between underpowered (PowerRRR30v50%) compared to adequately
powered studies, in subset A of 1,107 meta-analyses, overall and within medical specialties, outcome types and intervention-
comparison types.
Difference in log OR (95% CI) Between-meta-analysis standard deviation (95% CI)
Overall 20.10 (20.13, 20.08) 0.22 (0.22, 0.29)
By medical specialty 0.22 (0.21, 0.28)
Cancer 20.01 (20.08, 0.07)
Cardiovascular 20.12 (20.18, 20.06)
Central nervous system/musculoskeletal 0.04 (20.08, 0.16)
Digestive/endocr., nutritional and metabolic 20.01 (20.10, 0.08)
Gynaecology, pregnancy and birth 20.14 (20.19, 20.09)
Infectious diseases 20.20 (20.30, 20.09)
Mental health and behavioural conditions 20.15 (20.22, 20.08)
Pathological conditions, symptoms and signs 20.03 (20.18, 0.11)
Respiratory diseases 20.08 (20.17, 20.002)
Urogenital 20.06 (20.19, 0.06)
Other medical specialties1 20.21 (20.30, 20.12)
By outcome type 0.22 (0.22, 0.29)
All-cause mortality 20.08 (20.16, 20.003)
Semi-objective outcomes1 20.11 (20.15, 20.06)
Subjective outcomes1 20.11 (20.14, 20.08)
By intervention-comparison type 0.21(0.21, 0.29)
Pharmacological vs. Control/Placebo 20.15 (20.18, 20.11)
Non-pharmacological1 vs. Control/Placebo 20.12 (20.17, 20.07)
Active vs. Active2 20.03 (20.07, 0.01)
1Other medical specialties, semi-objective outcomes, subjective outcomes and non-pharmacological interventions defined in footnotes to Table 2.
2Comparison is less meaningful when comparing two active interventions since the a priori ‘‘better’’ active intervention is not taken into account.
doi:10.1371/journal.pone.0059202.t005
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meta-analyses. Some meta-analyses included a few very large
studies, which dominated their results, while in other meta-
analyses all studies were similarly sized and exclusion of
underpowered studies led to greater losses in precision.
On average, the between-study heterogeneity estimate de-
creased when underpowered studies were excluded from meta-
analyses, which may be expected since underpowered studies tend
to observe more extreme effect estimates. Within the subset of
1,107 meta-analyses examined, the heterogeneity estimate some-
times decreased substantially when underpowered studies were
removed. However, we also found examples where the heteroge-
neity increased when underpowered studies were removed, in
settings where, for example, the largest studies in the meta-analysis
had produced extremely different results.
The meta-analyses themselves were better powered than the
primary studies within meta-analyses, as we would expect: overall,
34% of CDSR meta-analyses had at least 50% power to detect
RRR30. Elsewhere, in the setting of cumulative meta-analysis in
particular, the information size required for a meta-analysis to
detect a particular effect size has been used to examine whether
meta-analyses contain enough information to be conclusive [19–
21]. Our finding that 22% of 14,886 meta-analyses were powered
at 80% or more for RRR30 is comparable with, but much more
precise than, the 39% of 174 meta-analyses from the Cochrane
Neonatal Group, which were found to meet the information size
criterion for RRR30 with 80% power by Brok et al. [20], who had,
however, excluded both reviews with fewer than three trials and
those in which all trials had a high risk of bias, in which meta-
analytic size is likely to have been smaller.
Our work is limited to meta-analyses from Cochrane reviews,
which may not be representative of meta-analyses in general. In
particular, the differences observed between medical areas may
reflect differing advice or editorial policies between Cochrane
Review Groups which oversee different medical areas rather than
disease-specific differences.
Although underpowered when included in meta-analyses, some
original studies may have been adequately powered for their own
primary outcomes, since the results extracted for meta-analysis
might have related to secondary outcomes. For example, a study
designed to detect a difference in measures of depression would be
unlikely to be adequately powered for all-cause mortality. We do
not therefore intend to criticise authors of primary studies for the
very low levels of power in these meta-analyses. Publication dates
of primary studies were not always available in the CDSR database,
and so we were unable to look at the association between study age
and power. It is possible that studies carried out in more recent
years were more generously powered. However, the reasons for
lack of power in completed studies include over-enthusiasm of
researchers for the effectiveness of a new intervention, problems
with recruitment to the study, and inaccurate sample size
calculations [22]; these issues are common in experimental
research and unlikely to disappear.
It is well known that small studies included in a meta-analysis
tend to show more extreme treatment effects than larger studies.
The differences observed between underpowered and adequately
powered studies in the CDSR data set are consistent with previous
findings, but offer much greater precision. For example, in a
combined analysis of 13 meta-analyses evaluating effects on pain
in patients with osteoarthritis, Nu¨esch et al. [23] found an average
difference of 20.21 (95% CI 20.34 to 20.08) in standardized
mean differences, when comparing trials with fewer than 100
patients per arm with larger trials. Several methods have been
proposed for addressing small study effects in meta-analysis;
recently, these were reviewed by Sterne et al. [24], who published
new guidelines.
The practical implications of our findings for systematic reviews
and meta-analyses vary according to review purpose and the
research time available. Systematic reviews commissioned to
inform public health policy decisions, by the National Institute for
Health and Clinical Excellence (NICE) for example, are often
carried out to tight deadlines [25]. Where a rapid review of the
evidence is required and if several large, high-quality studies have
been found in initial searches, it may be justifiable to truncate the
searching and perform the synthesis, since inclusion of more
obscure, smaller studies is unlikely to change the conclusions of the
review. On the other hand, many Cochrane reviews are carried
out in areas of scientific uncertainty, where discrepancies exist
between findings from previous, mainly small studies. Here, the
objective of meta-analysis is to resolve uncertainty by combining
all available evidence and investigating reasons for between-study
heterogeneity, and it would be inappropriate to leave out smaller
studies. When carrying out a rapid meta-analysis to inform a grant
application, the appropriate choice is less clear; although smaller
studies might add little information relative to the time required
for data extraction, it may be unethical to randomise yet more
patients if a meta-analysis including small, existing studies would
provide conclusive evidence.
In conclusion, we found that underpowered studies play a very
substantial role in meta-analyses reported by Cochrane reviews,
since the majority of meta-analyses include no adequately powered
studies. In meta-analyses including two or more adequately
powered studies, the remaining underpowered studies often
contributed little information to the combined results, and could
be left out if a rapid review of the evidence is required.
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